Effects of curative-intent lung cancer therapy on functional exercise capacity and patient-reported outcomes.

ABSTRACT: PURPOSE:Lung cancer treatment can lead to negative health consequences. We analyzed the effects of curative-intent lung cancer treatment on functional exercise capacity (EC) and patient-reported outcomes (PROs). METHODS:We performed a prospective, observational cohort study of consecutive patients with stage I-IIIA lung cancer undergoing curative-intent therapy and assessed functional EC (primary outcome, six-minute walk distance (6MWD)), cancer-specific quality of life (QoL) (secondary outcome, European Organization for Research and Treatment of Cancer QoL Questionnaire Core 30 (EORTC-QLQ-C30) summary score), and exploratory outcomes including dyspnea (University of California San Diego Shortness of Breath Questionnaire (UCSD SOBQ)) and fatigue Brief Fatigue Inventory (BFI)) symptoms before and at 1 to 3 months post-treatment. We analyzed the time effect of treatment on outcomes using multivariable generalized estimating equations. RESULTS:In 35 enrolled participants, treatment was associated with a clinically meaningful and borderline-significant decline in functional EC ((mean change, 95% CI) 6MWD?=?-?25.4 m (-?55.3, +?4.47), p?=?0.10), clinically meaningful and statistically significant higher dyspnea (UCSD SOBQ?=?+?13.1 (+?5.7, +?20.6), p?=?0.001) and fatigue (BFI?=?+?10.0 (+?2.9, +?17.0), p?=?0.006), but no clinically meaningful or statistically significant change in cancer-specific QoL (EORTC-QLQ-C30 summary score?=?-?3.4 (-?9.8, +?3.0), p?=?0.30). CONCLUSIONS:Among the first prospective analysis of the effect of curative-intent lung cancer treatment on functional EC and PROs, we observed worsening dyspnea and fatigue, and possibly a decline in functional EC but not cancer-specific QoL at 1 to 3 months post-treatment. Interventions to reduce treatment-related morbidities and improve lung cancer survivorship may need to focus on reducing dyspnea, fatigue, and/or improving functional EC.

SUBMITTER: Ha D 

PROVIDER: S-EPMC7371511 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature